U.S. markets closed

iCAD, Inc. (ICAD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.8100-0.1700 (-4.27%)
At close: 04:00PM EDT
3.8700 +0.06 (+1.57%)
After hours: 04:23PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.9800
Bid3.7600 x 1300
Ask3.8400 x 800
Day's Range3.6400 - 3.9800
52 Week Range2.9100 - 12.7300
Avg. Volume156,504
Market Cap95.943M
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-0.5240
Earnings DateAug 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ICAD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • icad inc.
    Analyst Report: Hologic, Inc.Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
    Fair Value
    Economic Moat
    12 days agoMorningstar
View more
  • GlobeNewswire

    iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022

    NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on August 10, 2022. August 10, 2022 at 4:30 PM ETDomestic: 888-506-0062 International: 973-528-0011 Conference ID: 718241 Webcast: https://www.webcaster4.c

  • Simply Wall St.

    Here's What iCAD, Inc.'s (NASDAQ:ICAD) Shareholder Ownership Structure Looks Like

    The big shareholder groups in iCAD, Inc. ( NASDAQ:ICAD ) have power over the company. Large companies usually have...

  • GlobeNewswire

    iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology

    Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women with 32 times higher risk of breast cancer than the general populationNASHUA, N.H., July 13, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company will showcase and demonstrate the complete portfolio of its Breast AI solutions, including ProFound AI®, PowerLook® Density A